Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Federal Institute of Technology Lab to Use VisEn's Fluorescence Probes

NEW YORK (GenomeWeb News) – VisEn Medical today said that the Swiss Federal Institute of Technology will use its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system in its molecular imaging programs.
 
VisEn said its technologies are designed to identify, characterize, and quantify a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease, and bone disease.
 
The technology will be used in the lab of Markus Rudin, whom the company has appointed to its scientific advisory board.
 
Rudin is a professor of molecular imaging and functional pharmacology at the Swiss Federal Institute of Technology and the University of Zürich. He has been the head of imaging technologies at Novartis.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.